| Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273) |
|---|
| 04/24/2003 | US20030077287 Methods to improve immunogenicity of antigens and specificity of antibodies |
| 04/24/2003 | CA2727642A1 Synthesis of cyclosporin analogs |
| 04/24/2003 | CA2463994A1 Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications |
| 04/24/2003 | CA2463911A1 Tumor targeted photodiagnostic-phototherapeutic agents |
| 04/24/2003 | CA2463908A1 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 04/24/2003 | CA2463906A1 Pathological tissue detection and treatment employing targeted benzoindole optical agents |
| 04/24/2003 | CA2462713A1 Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone |
| 04/24/2003 | CA2461740A1 Synthesis of cyclosporin analogs |
| 04/24/2003 | CA2461575A1 Use of peptide vectors to improve the immune response to antigens |
| 04/24/2003 | CA2461542A1 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | CA2461170A1 Peptidyl ketones as inhibitors of dpiv |
| 04/24/2003 | CA2460685A1 Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 04/23/2003 | EP1303538A2 Ghrelin antagonists |
| 04/23/2003 | EP1303533A2 Chimeric peptide immunogens, their preparation and use |
| 04/23/2003 | EP1303487A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 04/23/2003 | EP1117681B1 Rho-cocotoxin peptides having selective alpha-1 adrenoceptor activity |
| 04/23/2003 | EP0988394A4 Compositions for the detection of enzyme activity in biological samples and methods of use thereof |
| 04/23/2003 | EP0871654B1 Protegrins |
| 04/23/2003 | EP0861266B1 Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them |
| 04/23/2003 | CN1412197A 17 peptide organic compound and its application |
| 04/22/2003 | US6552180 Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-2 and uses thereof |
| 04/22/2003 | US6552167 Chemically modifying target molecules, e. g. macromolecules, particularly biologically important polypeptides, and surfaces (e.g., gold or glass) by means of covalent attachment of polyamide chains of precise length |
| 04/22/2003 | US6551998 Therapy and prophylaxis of bacterial infection in a mammal by administering peptide antibiotic compound |
| 04/22/2003 | US6551799 Nucleotide sequences coding polypeptide for use in diagnosis and treatment of pancreatic defects |
| 04/22/2003 | US6551574 Tuftsin receptor-specific peptides, peptidomimetics and peptide-like constructs for use in biological, pharmaceutical and radiopharmaceutical applications, in which peptide is conformationally fixed on complexation with metal ion |
| 04/22/2003 | CA2113995C Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins |
| 04/22/2003 | CA2101075C Peptides for the treatment of conditions caused by herpes virus infections |
| 04/22/2003 | CA2096975C Cell stress transcriptional factors |
| 04/17/2003 | WO2003031589A2 Peptides and related compounds having thrombopoietic activity |
| 04/17/2003 | WO2003031467A2 Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament |
| 04/17/2003 | WO2003031449A2 Cross-linked glycopeptide-cephalosporin antibiotics |
| 04/17/2003 | WO2003030927A2 Use of thymulin-like peptides for making pain-relieving medicines |
| 04/17/2003 | WO2003030925A1 Angiogenesis drugs |
| 04/17/2003 | WO2003030834A2 Cyclosporin analogs for the treatment of lung diseases |
| 04/17/2003 | WO2002094985A3 Beta-secretase substrates and uses thereof |
| 04/17/2003 | WO2002085928A3 Modified cyclosporine which can be used as a pro-drug and use thereof |
| 04/17/2003 | WO2002069902A3 Cyclosporins for the treatment of respiratory diseases |
| 04/17/2003 | WO2002032291A9 Imaging of enzymatic activity |
| 04/17/2003 | WO2001098366A3 Enterokinase cleavage sequences and their use |
| 04/17/2003 | WO1999056766A3 Method for treating ischemia |
| 04/17/2003 | WO1994020127A9 Hla-a2.1 binding peptides and their uses |
| 04/17/2003 | US20030073852 Anticancer agents |
| 04/17/2003 | US20030073808 Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases |
| 04/17/2003 | US20030073807 Bi-directional synthesis of oligoguanidine transport agents |
| 04/17/2003 | US20030073721 Central nervous system disorders; Alzheimer's disease; genetic engineering |
| 04/17/2003 | US20030073628 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 04/17/2003 | US20030073616 Hair growth; controlling apolecia |
| 04/17/2003 | US20030073157 Synthetic peptides, conjugation reagents and methods |
| 04/17/2003 | US20030072775 For immunization; for therapy of disseminated candidiasis |
| 04/17/2003 | CA2461429A1 Peptides and related compounds having thrombopoietic activity |
| 04/16/2003 | EP1301604A2 Substrates and assays for beta-secretase activity |
| 04/16/2003 | EP1301540A2 Rgd (arg-gly-asp) coupled to neuropeptides |
| 04/16/2003 | EP1301539A2 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 04/16/2003 | EP1301530A2 Multiple antigenic peptides immunogenic against streptococcus pneumoniae |
| 04/16/2003 | EP1301528A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 04/16/2003 | EP1301527A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 04/16/2003 | EP1301486A2 Imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 04/16/2003 | EP1301213A2 Multi-component biological transport systems |
| 04/16/2003 | EP0804481B1 Somatostatin derivatives and their radiolabelled products |
| 04/16/2003 | EP0789591B1 Methods for identifying individuals suffering from a cellular abnormality |
| 04/16/2003 | EP0769958B1 Inhibitors of leukocyte adhesion |
| 04/16/2003 | EP0750508B1 RETROPEPTIDES, ANTIBODIES THERETO, AND USES THEREOF FOR VACCINATION AND $i(IN VITRO) DIAGNOSIS |
| 04/16/2003 | EP0749443B1 Fk-506 cytosolic binding protein |
| 04/16/2003 | CN1411467A Compounds and use thereof to modify transport across cell membranes |
| 04/16/2003 | CN1410447A Sequence number3 bioactive peptide |
| 04/16/2003 | CN1410446A Sequence number4 bioactive peptide |
| 04/16/2003 | CN1410445A Sequence number5 bioactive peptide |
| 04/16/2003 | CN1410444A Sequence number9 bioactive peptide |
| 04/16/2003 | CN1410443A Sequence number8 bioactive peptide |
| 04/16/2003 | CN1410442A Sequence number1 bioactive peptide |
| 04/16/2003 | CN1410441A Sequence number2 bioactive peptide |
| 04/16/2003 | CN1410440A Sequence number6 bioactive peptide |
| 04/16/2003 | CN1410439A Sequence number10 bioactive peptide |
| 04/16/2003 | CN1410438A Sequence no.25 bioactive peptide |
| 04/16/2003 | CN1105574C Therapeutic uses of bactericidal/permeability increasing protein products |
| 04/15/2003 | US6548663 Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
| 04/15/2003 | US6548634 Peptidic composition linked to an oligomerization domain directly or through a linker or heparin binding domain; no homology to naturally occuring fibroblast growth factors (fgf) |
| 04/15/2003 | US6548630 Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
| 04/15/2003 | US6548479 Fused bicyclic peptides are administered to an animal to inhibit the proliferation of CD4 T-cells |
| 04/15/2003 | US6548476 Dimeric inhibitors of influenza neuraminidase |
| 04/11/2003 | WO2002030961A1 Novel peptides |
| 04/11/2003 | CA2425769A1 Novel peptides |
| 04/10/2003 | WO2003029428A2 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
| 04/10/2003 | WO2003029292A2 Gene regulatory peptides |
| 04/10/2003 | WO2003029288A2 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same |
| 04/10/2003 | WO2003029282A2 Tumor-peptide antigens from the human prdi-bf1-protein |
| 04/10/2003 | WO2003028858A1 Process for ultrafiltration of an antifungal agent |
| 04/10/2003 | WO2003028527A2 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 04/10/2003 | WO2003002092A3 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 04/10/2003 | WO2002098448A9 Methods and compositions for modulating ace-2 activity |
| 04/10/2003 | WO2002081504A3 Multimerization of hiv-1 vif protein as a therapeutic target |
| 04/10/2003 | WO2002053173A3 Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases |
| 04/10/2003 | WO2001083693A3 Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses |
| 04/10/2003 | US20030069395 Serum albumin conjugate for use in the transfer and delivery of therapeutic agent to target |
| 04/10/2003 | US20030069186 Chimeric natriuretic peptides |
| 04/10/2003 | US20030069181 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 04/10/2003 | US20030069177 Contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor. |
| 04/10/2003 | US20030069175 A cyclic peptide, e.g., cyclic (Tyr-Gly-Phe-Gly-Gly) useful for stimulating the formation of osteoblastic or fibroblastic cells, enhancing bone formation, repairing fractures, healing wounds, grafting intraosseous implants, etc. |
| 04/10/2003 | US20030069173 Peptide-enhanced transfections |
| 04/10/2003 | US20030068900 Biological control of nanoparticle nucleation, shape and crystal phase |